| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.03 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.04 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.083 | 0.04 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.04 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.077 | 0.04 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | 0.076 | 0.04 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.066 | 0.04 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.04 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.04 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.04 |